Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
Open Access
- 3 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Calcified Tissue International
- Vol. 89 (2), 91-104
- https://doi.org/10.1007/s00223-011-9499-8
Abstract
The pharmacological management of disease should involve consideration of the balance between the beneficial effects of treatment on outcome and the probability of adverse effects. The aim of this review is to explore the risk of adverse drug reactions and drug–drug interactions with treatments for postmenopausal osteoporosis. We reviewed evidence for adverse reactions from regulatory documents, randomized controlled trials, pharmacovigilance surveys, and case series. Bisphosphonates are associated with gastrointestinal effects, musculoskeletal pain, and acute-phase reactions, as well as, very rarely, atrial fibrillation, atypical fracture, delayed fracture healing, osteonecrosis of the jaw, hypersensitivity reactions, and renal impairment. Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. Strontium ranelate has been linked to hypersensitivity reactions and venous thromboembolism (both very rare) and teriparatide with headache, nausea, dizziness, and limb pain. The solidity of the evidence base depends on the frequency of the reaction, and causality is not always easy to establish for the very rare adverse reactions. Drug–drug interactions are rare. Osteoporosis treatments are generally safe and well tolerated, though they are associated with a few very rare serious adverse reactions. While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture.Keywords
This publication has 111 references indexed in Scilit:
- Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportOsteoporosis International, 2010
- Exposure to Oral Bisphosphonates and Risk of Esophageal CancerJama-Journal Of The American Medical Association, 2010
- Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research DatabaseOsteoporosis International, 2009
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate CancerNew England Journal of Medicine, 2009
- Adverse Effects of Bisphosphonates: Implications for Osteoporosis ManagementMayo Clinic Proceedings, 2009
- The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UKOsteoporosis International, 2009
- Risks and benefits of bisphosphonatesBritish Journal of Cancer, 2008
- Inter‐expert agreement of seven criteria in causality assessment of adverse drug reactionsBritish Journal of Clinical Pharmacology, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJama-Journal Of The American Medical Association, 2006